Efficacy, safety, and quality of life of dabrafenib plus trametinib treatment in Chinese patients with BRAFV600E mutation-positive metastatic non-small cell lung cancer

Abstract excerpt

Background: Dabrafenib plus trametinib (Dab + Tram) is an approved targeted therapy in patients with BRAFV600+ mutated metastatic non-small cell lung cancer (NSCLC). Here, we report the efficacy, safety, and quality of life (QoL) results of Dab + Tram treatment in Chinese patients with BRAFV600E mutation-positive metastatic NSCLC. Methods: This is a single-arm, open-label, multicentre, phase II study...

Topics

Join the communities discussing this publication.

• Lung Cancer Research Studies
• Lung Cancer Treatments and Mutations
• Melanoma and MAPK Pathways